NanoRepro AG

Equities

NN6

DE0006577109

Medical Equipment, Supplies & Distribution

Real-time Estimate Tradegate Other stock markets 04:37:32 2024-05-09 EDT			5-day change	1st Jan Change
1.8 ^EUR	-2.44%		+0.82%	-7.52%

2023	NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	NanoRepro AG commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 29, 2022.	CI

NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2021

September 23, 2021 at 03:27 am

NanoRepro AG announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was EUR 119.974 million compared to EUR 2.207 million a year ago. Operating income was EUR 34.672 million compared to EUR 468,373.28 a year ago. Net income was EUR 25.916 million compared to EUR 323,441.06 a year ago.

Latest news about NanoRepro AG

NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-31	CI
NanoRepro AG commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 29, 2022.	23-05-21	CI
NanoRepro AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-04	CI
NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-27	CI
NanoRepro AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-13	CI
NanoRepro to Supply 41 Million Rapid COVID-19 Antigen Tests to Viromed	21-11-24	MT
NanoRepro AG Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-23	CI
NanoRepro : Secures CE Mark on Two SARS-CoV-2 Tests	21-06-14	MT
Nanorepro Ag Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-20	CI
NanoRepro AG announced that it has received €0.9 million in funding	17-11-05	CI
NanoRepro AG Signs Distribution Agreement for Romania, Moldova	15-06-18	CI
NanoRepro AG (DB:NN6) acquired brand alphabiol from Alphablom AG.	15-03-03	CI

Chart NanoRepro AG

Duration

Period

More charts

Company Profile

Nanorepro AG is a Germany-based company active in the biotechnology sector. The Company is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patientsâ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOREPRO AG	-7.52%	25.53M
ABBOTT LABORATORIES	-4.66%	183B
MEDTRONIC PLC	-1.01%	108B
BECTON, DICKINSON AND COMPANY	-4.20%	67.51B
DEXCOM, INC.	+2.68%	50.67B
CENCORA, INC.	+9.12%	44.7B
HOYA CORPORATION	+2.41%	40.95B
WEST PHARMACEUTICAL SERVICES, INC.	+4.13%	26.71B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.31%	26.8B
TERUMO CORPORATION	+12.66%	24.62B

Other Medical Equipment, Supplies & Distribution